Pembrolizumab History and Updates

250 events · 2010 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

131
FDA Approvals
0
Label Revisions
7,863
Trial Milestones
0
Pivotal Publications
Pembrolizumab — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications20102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041204220432044Trial: NCT04266730 2027-05-20 → 2027-06-01 (primary completion)Trial: NCT07689240 2027-02-10 → 2032-01-01 (primary completion)Trial: NCT07765433 2027-01-11 → 2028-12-31 (primary completion)Trial: NCT07037004 2027-01-01 → 2028-10-24 (primary completion)Trial: NCT06724042 2026-12-30 → 2029-12-30 (primary completion)Trial: NCT07572123 2026-12-04 → 2029-03-31 (primary completion)Trial: NCT07667335 2026-12-01 → 2029-07-16 (primary completion)Trial: NCT07610525 2026-11-05 → 2029-01-15 (primary completion)Trial: NCT07639242 2026-10-31 → 2030-06-21 (primary completion)Trial: NCT07643519 2026-10-31 → 2029-02-28 (primary completion)Trial: NCT07773987 2026-10-31 → 2029-10-31 (primary completion)Trial: NCT07715396 2026-10-30 → 2031-10-30 (primary completion)Trial: NCT07578649 2026-10-09 → 2029-06-01 (primary completion)Trial: NCT07021989 2026-10-01 → 2029-07-31 (primary completion)Trial: NCT07275216 2026-10-01 → 2029-10-20 (primary completion)Trial: NCT07743190 2026-10-01 → 2029-03-01 (primary completion)Trial: NCT07770100 2026-10-01 → 2040-02-28 (primary completion)Trial: NCT07786428 2026-10-01 → 2029-10-31 (primary completion)Trial: NCT07788664 2026-10-01 → 2030-06-01 (primary completion)Trial: NCT07739966 2026-10-01 → 2030-07-31 (primary completion)Trial: NCT07552558 2026-09-30 → 2028-11-30 (primary completion)Trial: NCT07744126 2026-09-30 → 2029-10-31 (primary completion)Trial: NCT07762703 2026-09-30 → 2030-09-30 (primary completion)Trial: NCT07762716 2026-09-30 → 2030-09-30 (primary completion)Trial: NCT07680088 2026-09-30 → 2028-09-30 (primary completion)Trial: NCT07756645 2026-09-22 → 2029-12-31 (primary completion)Trial: NCT07420439 2026-09-15 → 2028-08-15 (primary completion)Trial: NCT07619599 2026-09-14 → 2028-12-22 (primary completion)Trial: NCT07783581 2026-09-07 → 2030-04-01 (primary completion)Trial: NCT07684599 2026-09-03 → 2029-07-23 (primary completion)Trial: NCT07388550 2026-09-02 → 2028-01-01 (primary completion)Trial: NCT07594015 2026-09-01 → 2031-09-01 (primary completion)Trial: NCT07663747 2026-09-01 → 2031-04-01 (primary completion)Trial: NCT07629700 2026-09-01 → 2027-09-01 (primary completion)Trial: NCT07541170 2026-09-01 → 2032-01-31 (primary completion)Trial: NCT07341867 2026-08-31 → 2028-03-31 (primary completion)Trial: NCT07732634 2026-08-31 → 2029-08-31 (primary completion)Trial: NCT07634094 2026-08-31 → 2028-08-31 (primary completion)Trial: NCT07730021 2026-08-31 → 2030-02-28 (primary completion)Trial: NCT07178730 2026-08-30 → 2033-03-31 (primary completion)Trial: NCT06863402 2026-08-15 → 2029-06-01 (primary completion)Trial: NCT07740941 2026-08-05 → 2029-03-31 (primary completion)Trial: NCT07300475 2026-08-01 → 2030-05-31 (primary completion)Trial: NCT07622186 2026-07-31 → 2028-12-31 (primary completion)Trial: NCT07360743 2026-07-30 → 2028-06-30 (primary completion)Trial: NCT07565285 2026-07-01 → 2027-12-31 (primary completion)Trial: NCT07484022 2026-06-30 → 2027-06-30 (primary completion)Trial: NCT07484139 2026-06-30 → 2028-05-31 (primary completion)Trial: NCT07652242 2026-06-30 → 2028-02-29 (primary completion)Trial: NCT07452224 2026-06-30 → 2029-06-30 (primary completion)Trial: NCT07593040 2026-06-30 → 2028-01-31 (primary completion)Trial: NCT07673887 2026-06-30 → 2031-02-28 (primary completion)Trial: NCT07302347 2026-06-30 → 2029-03-30 (primary completion)Trial: NCT07015853 2026-06-30 → 2033-07-31 (primary completion)Trial: NCT07267338 2026-06-30 → 2027-12-31 (primary completion)Trial: NCT07286266 2026-06-24 → 2030-08-21 (primary completion)Trial: NCT07486817 2026-06-22 → 2027-08-12 (primary completion)Trial: NCT07475572 2026-06-19 → 2027-10-31 (primary completion)Trial: NCT07383441 2026-06-10 → 2033-01-31 (primary completion)Trial: NCT07283731 2026-06-02 → 2028-11-01 (primary completion)Trial: NCT07385846 2026-06-01 → 2028-06-01 (primary completion)Trial: NCT07591597 2026-05-31 → 2027-07-31 (primary completion)Trial: NCT07346053 2026-05-31 → 2030-12-31 (primary completion)Trial: NCT07524257 2026-05-29 → 2029-05-15 (primary completion)Trial: NCT07365319 2026-05-18 → 2035-12-31 (primary completion)Trial: NCT07415031 2026-05-16 → 2028-02-16 (primary completion)Trial: NCT07566156 2026-05-11 → 2030-03-31 (primary completion)Trial: NCT07264075 2026-04-30 → 2030-05-31 (primary completion)Trial: NCT07172256 2026-04-30 → 2031-02-28 (primary completion)Trial: NCT07343596 2026-04-15 → 2027-12-31 (primary completion)Trial: NCT07455032 2026-04-08 → 2027-11-30 (primary completion)Trial: NCT07017829 2026-04-01 → 2028-12-01 (primary completion)Trial: NCT07301268 2026-04-01 → 2029-04-30 (primary completion)Trial: NCT07509099 2026-04-01 → 2030-09-30 (primary completion)Trial: NCT06400160 2026-03-31 → 2027-03-31 (primary completion)Trial: NCT07318883 2026-03-31 → 2031-01-31 (primary completion)Trial: NCT05741164 2026-03-30 → 2028-06-30 (primary completion)Trial: NCT07465276 2026-03-26 → 2028-04-30 (primary completion)Trial: NCT07027124 2026-03-19 → 2027-12-01 (primary completion)Trial: NCT07501650 2026-03-18 → 2027-03-31 (primary completion)Trial: NCT07469774 2026-03-17 → 2027-12-31 (primary completion)Trial: NCT07276880 2026-03-17 → 2027-11-30 (primary completion)Trial: NCT07466927 2026-03-15 → 2028-01-15 (primary completion)Trial: NCT07485179 2026-03-12 → 2026-09-12 (primary completion)Trial: NCT07290894 2026-03-12 → 2031-10-31 (primary completion)Trial: NCT07475806 2026-03-12 → 2027-11-30 (primary completion)Trial: NCT07361510 2026-03-12 → 2031-10-14 (primary completion)Trial: NCT07412054 2026-03-01 → 2027-06-01 (primary completion)Trial: NCT07199413 2026-03-01 → 2029-04-01 (primary completion)Trial: NCT07409844 2026-03-01 → 2028-03-01 (primary completion)Trial: NCT07404332 2026-02-28 → 2028-02-28 (primary completion)Trial: NCT07394062 2026-02-28 → 2027-08-31 (primary completion)Trial: NCT07327229 2026-02-27 → 2027-09-30 (primary completion)Trial: NCT07217496 2026-02-15 → 2027-05-30 (primary completion)Trial: NCT07232602 2026-02-09 → 2031-07-08 (primary completion)Trial: NCT07287995 2026-02-05 → 2029-06-30 (primary completion)Trial: NCT07264816 2026-02-03 → 2027-12-31 (primary completion)Trial: NCT07410676 2026-02-01 → 2028-12-21 (primary completion)Trial: NCT06749925 2026-01-31 → 2028-01-31 (primary completion)Trial: NCT04901741 2026-01-31 → 2028-03-31 (primary completion)Trial: NCT07347210 2026-01-31 → 2029-01-31 (primary completion)Trial: NCT07198074 2026-01-27 → 2028-07-01 (primary completion)Trial: NCT07287917 2026-01-26 → 2028-02-28 (primary completion)Trial: NCT07221942 2026-01-23 → 2028-09-01 (primary completion)Trial: NCT06041503 2026-01-20 → 2027-10-01 (primary completion)Trial: NCT07262619 2026-01-20 → 2029-03-31 (primary completion)Trial: NCT07188246 2026-01-19 → 2027-07-31 (primary completion)Trial: NCT07216703 2026-01-19 → 2031-10-29 (primary completion)Trial: NCT07183319 2026-01-19 → 2028-03-31 (primary completion)Trial: NCT07176312 2026-01-16 → 2029-03-31 (primary completion)Trial: NCT07195695 2026-01-16 → 2032-02-26 (primary completion)Trial: NCT07349303 2026-01-15 → 2029-05-15 (primary completion)Trial: NCT06898970 2026-01-09 → 2029-10-31 (primary completion)Trial: NCT07222566 2026-01-06 → 2029-02-27 (primary completion)Trial: NCT07063745 2026-01-02 → 2031-08-12 (primary completion)Trial: NCT07315750 2026-01-01 → 2029-06-30 (primary completion)Trial: NCT07244393 2025-12-31 → 2029-04-30 (primary completion)Trial: NCT07269158 2025-12-31 → 2029-09-30 (primary completion)Trial: NCT06405230 2025-12-30 → 2028-08-07 (primary completion)Trial: NCT07362459 2025-12-30 → 2027-07-31 (primary completion)Trial: NCT07187778 2025-12-19 → 2027-07-19 (primary completion)Trial: NCT07252739 2025-12-19 → 2033-01-14 (primary completion)Trial: NCT07247110 2025-12-16 → 2030-12-01 (primary completion)Trial: NCT07221474 2025-12-12 → 2029-07-02 (primary completion)Trial: NCT07218380 2025-12-12 → 2029-10-31 (primary completion)Trial: NCT06947928 2025-12-11 → 2027-03-31 (primary completion)Trial: NCT06908993 2025-12-09 → 2028-03-15 (primary completion)Trial: NCT07089992 2025-12-04 → 2028-12-31 (primary completion)Trial: NCT07276399 2025-12-03 → 2029-06-18 (primary completion)Trial: NCT07283822 2025-12-03 → 2028-01-31 (primary completion)Trial: NCT06324240 2025-12-02 → 2026-12-31 (primary completion)Trial: NCT06524544 2025-12-02 → 2030-12-31 (primary completion)Trial: NCT07223047 2025-11-25 → 2028-10-13 (primary completion)Trial: NCT07061964 2025-11-25 → 2027-07-31 (primary completion)Trial: NCT07095868 2025-11-17 → 2029-11-30 (primary completion)Trial: NCT07218003 2025-11-17 → 2029-02-28 (primary completion)Trial: NCT07255664 2025-11-13 → 2027-04-30 (primary completion)Trial: NCT07227168 2025-11-07 → 2027-12-31 (primary completion)Trial: NCT07061977 2025-11-05 → 2030-12-31 (primary completion)Trial: NCT07223424 2025-11-04 → 2030-11-30 (primary completion)Trial: NCT07129772 2025-11-01 → 2027-12-31 (primary completion)Trial: NCT07090369 2025-11-01 → 2028-12-01 (primary completion)Trial: NCT06940440 2025-10-31 → 2026-05-31 (primary completion)Trial: NCT07026474 2025-10-30 → 2032-12-31 (primary completion)Trial: NCT04129515 2025-10-30 → 2025-12-31 (primary completion)Trial: NCT07123415 2025-10-24 → 2028-10-31 (primary completion)Trial: NCT06899126 2025-10-24 → 2030-04-24 (primary completion)Trial: NCT06793215 2025-10-24 → 2028-11-30 (primary completion)Trial: NCT06492759 2025-10-22 → 2027-02-12 (primary completion)Trial: NCT06845319 2025-10-20 → 2027-10-20 (primary completion)Trial: NCT07215637 2025-10-16 → 2027-03-31 (primary completion)Trial: NCT07180862 2025-10-14 → 2027-02-28 (primary completion)Trial: NCT07231458 2025-10-14 → 2026-10-30 (primary completion)Trial: NCT07166601 2025-10-10 → 2029-02-23 (primary completion)Trial: NCT07407920 2025-10-09 → 2026-09-30 (primary completion)Trial: NCT07190248 2025-10-08 → 2029-12-07 (primary completion)Trial: NCT07213934 2025-10-08 → 2030-12-31 (primary completion)Trial: NCT07174453 2025-10-07 → 2027-10-01 (primary completion)Trial: NCT07182591 2025-10-02 → 2030-03-18 (primary completion)Trial: NCT06361810 2025-10-01 → 2031-01-31 (primary completion)Trial: NCT06822543 2025-09-30 → 2028-06-30 (primary completion)Trial: NCT06646445 2025-09-30 → 2027-12-31 (primary completion)Trial: NCT06912087 2025-09-29 → 2027-06-05 (primary completion)Trial: NCT07178795 2025-09-29 → 2027-12-31 (primary completion)Trial: NCT07160335 2025-09-26 → 2027-04-30 (primary completion)Trial: NCT06161545 2025-09-24 → 2026-12-01 (primary completion)Trial: NCT05668949 2025-09-23 → 2025-09-23 (primary completion)Trial: NCT07111520 2025-09-22 → 2029-01-31 (primary completion)Trial: NCT07082439 2025-09-10 → 2027-09-30 (primary completion)Trial: NCT07016399 2025-09-09 → 2028-09-01 (primary completion)Trial: NCT07162883 2025-09-01 → 2026-12-31 (primary completion)Trial: NCT06951399 2025-09-01 → 2027-08-30 (primary completion)Trial: NCT06045195 2025-08-31 → 2027-01-31 (primary completion)Trial: NCT07159217 2025-08-30 → 2027-05-31 (primary completion)Trial: NCT06998069 2025-08-27 → 2026-12-01 (primary completion)Trial: NCT07122687 2025-08-26 → 2026-11-30 (primary completion)Trial: NCT07054567 2025-08-21 → 2027-05-31 (primary completion)Trial: NCT07158918 2025-08-06 → 2027-12-02 (primary completion)Trial: NCT06624644 2025-08-06 → 2029-02-28 (primary completion)Trial: NCT07092670 2025-08-04 → 2028-08-01 (primary completion)Trial: NCT07087860 2025-08-01 → 2028-08-07 (primary completion)Trial: NCT07136545 2025-08-01 → 2026-12-31 (primary completion)Trial: NCT07094113 2025-07-31 → 2028-04-18 (primary completion)Trial: NCT06780111 2025-07-30 → 2032-01-04 (primary completion)Trial: NCT06543576 2025-07-29 → 2031-01-31 (primary completion)Trial: NCT06962787 2025-07-28 → 2027-05-31 (primary completion)Trial: NCT06984328 2025-07-25 → 2027-07-15 (primary completion)Trial: NCT07018570 2025-07-24 → 2030-06-30 (primary completion)Trial: NCT07061379 2025-07-24 → 2027-06-30 (primary completion)Trial: NCT06606730 2025-07-23 → 2033-01-01 (primary completion)Trial: NCT06758401 2025-07-23 → 2028-09-05 (primary completion)Trial: NCT06960395 2025-07-22 → 2029-08-31 (primary completion)Trial: NCT06356155 2025-07-22 → 2028-03-31 (primary completion)Trial: NCT07067450 2025-07-20 → 2026-12-31 (primary completion)Trial: NCT04645602 2025-07-18 → 2027-12-31 (primary completion)Trial: NCT06669572 2025-07-11 → 2029-03-26 (primary completion)Trial: NCT05879484 2025-07-09 → 2025-07-09 (primary completion)Trial: NCT06963814 2025-07-04 → 2026-05-30 (primary completion)Trial: NCT06939036 2025-07-01 → 2025-12-31 (primary completion)Trial: NCT07010393 2025-07-01 → 2027-12-31 (primary completion)FDA approval — 2014-09-04 FDA approved Keytruda (pembrolizumab) (BLA 125514) Sponsor: MERCK SHARP DOHME. Class: Type 1 - New Molecular Entity.FDA approval (supplemental) — 2015-06-19 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-3) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2015-10-02 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-5) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2015-12-18 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-6) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2015-12-18 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-4) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2016-08-05 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-9) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2016-10-24 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-12) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2016-10-24 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-8) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2017-03-14 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-15) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2017-05-10 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-16) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2017-05-17 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-13) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2017-05-18 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-17) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2017-05-18 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-18) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2017-05-23 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-14) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2017-07-27 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-19) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2017-07-27 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-23) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2017-09-22 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-24) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2017-11-29 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-31) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2018-06-12 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-34) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2018-06-13 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-30) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2018-06-19 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-43) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2018-08-16 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-46) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2018-08-20 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-35) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2018-10-30 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-41) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2018-11-09 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-42) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2018-12-19 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-45) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2018-12-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-37) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2019-02-15 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-40) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2019-04-11 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-47) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2019-04-19 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-54) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2019-06-10 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-52) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2019-06-17 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-53) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2019-07-30 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-56) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2019-07-30 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-55) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2019-09-17 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-65) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-01-08 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-66) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-01-09 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-67) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-64) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-78) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-76) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-69) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-61) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-63) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-59) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-62) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-81) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-79) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-82) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-83) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-60) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-77) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-04-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-80) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-06-16 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-71) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-06-16 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-90) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-06-24 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-68) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-06-24 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-92) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-06-29 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-84) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-10-02 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-70) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-10-14 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-85) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2020-11-10 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-48) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2020-11-13 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-88) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-02-10 FDA approved supplemental application for Keytruda (pembrolizumab) — Manufacturing (CMC) (BLA 125514 S-98) Sponsor: MERCK SHARP DOHME. Class: Manufacturing (CMC).FDA approval (supplemental) — 2021-03-16 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-91) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-03-16 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-93) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-03-22 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-96) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-03-30 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-106) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2021-05-05 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-97) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-06-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-108) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2021-07-01 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-100) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-07-21 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-105) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-07-26 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-89) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-07-26 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-114) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-08-03 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-104) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2021-08-10 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-102) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-08-31 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-118) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-08-31 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-117) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-10-13 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-122) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-10-13 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-121) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-11-17 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-113) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-12-03 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-112) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2021-12-17 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-120) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2022-02-04 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-125) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2022-02-04 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-95) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2022-03-21 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-110) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2022-05-20 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-123) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2022-06-21 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-131) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2022-08-05 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-133) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2022-12-16 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-127) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-01-26 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-128) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-03-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-132) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-04-03 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-136) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-08-14 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-135) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-08-14 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-134) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-10-12 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-138) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-10-16 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-139) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-10-23 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-142) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-10-31 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-144) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-10-31 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-145) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-11-07 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-148) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-11-16 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-143) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-12-15 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-151) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2023-12-15 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-152) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2024-01-12 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-147) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2024-01-25 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-124) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2024-03-11 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-160) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2024-06-07 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-154) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2024-06-17 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-155) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2024-07-31 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-158) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2024-08-07 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-157) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2024-09-17 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-161) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2024-11-20 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-164) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2024-12-11 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-162) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-01-28 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-172) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-03-19 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-170) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-04-21 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-174) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-05-22 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-182) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-06-03 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-173) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-06-06 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-183) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-06-12 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-180) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-07-24 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-178) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval — 2025-09-19 FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) (BLA 761467) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval — 2025-09-19 FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) (BLA 761467) Sponsor: MERCK SHARP DOHME. Class: Type 1 - New Molecular Entity.FDA approval (supplemental) — 2025-11-21 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-188) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2025-11-21 FDA approved supplemental application for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) — Efficacy (BLA 761467 S-1) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2026-02-10 FDA approved supplemental application for Keytruda (pembrolizumab) — Efficacy (BLA 125514 S-186) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2026-02-10 FDA approved supplemental application for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) — Efficacy (BLA 761467 S-2) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2026-04-06 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-195) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2026-04-06 FDA approved supplemental application for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) — Labeling (BLA 761467 S-13) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2026-04-24 FDA approved supplemental application for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) — Efficacy (BLA 761467 S-3) Sponsor: MERCK SHARP DOHME. Class: Efficacy.FDA approval (supplemental) — 2026-05-12 FDA approved supplemental application for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) — Labeling (BLA 761467 S-7) Sponsor: MERCK SHARP DOHME. Class: Labeling.FDA approval (supplemental) — 2026-05-12 FDA approved supplemental application for Keytruda (pembrolizumab) — Labeling (BLA 125514 S-190) Sponsor: MERCK SHARP DOHME. Class: Labeling.Results posted — 2024-11-08 Trial results posted: NCT02791594 Imaging FDG Flare in MelanomaResults posted — 2024-11-12 Trial results posted: NCT04135352 A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/MetasResults posted — 2024-11-14 Trial results posted: NCT03769467 Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Results posted — 2024-11-15 Trial results posted: NCT02844075 Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)Results posted — 2024-11-18 Trial results posted: NCT02619253 Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell CarcinomaResults posted — 2024-11-19 Trial results posted: NCT03761914 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersResults posted — 2024-11-20 Trial results posted: NCT03486197 Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial CarcinomaResults posted — 2024-11-20 Trial results posted: NCT03248570 Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsResults posted — 2024-11-21 Trial results posted: NCT02972034 Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)Results posted — 2024-11-22 Trial results posted: NCT03514121 FPA150 in Patients With Advanced Solid TumorsResults posted — 2024-11-26 Trial results posted: NCT03534804 Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaResults posted — 2024-11-29 Trial results posted: NCT04508140 Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver MetastasisResults posted — 2024-12-02 Trial results posted: NCT03032107 A Study Of Pembrolizumab In Combination With Trastuzumab-DM1Results posted — 2024-12-10 Trial results posted: NCT02784171 Pembrolizumab in Patients With Advanced Malignant Pleural MesotheliomaResults posted — 2024-12-11 Trial results posted: NCT03632941 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast CancerResults posted — 2024-12-16 Trial results posted: NCT04555837 Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerResults posted — 2024-12-17 Trial results posted: NCT05446870 Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)Results posted — 2024-12-17 Trial results posted: NCT04306367 Study of Pembrolizumab and Olaparib in Bile Duct CancerResults posted — 2024-12-18 Trial results posted: NCT03625323 Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated UnresResults posted — 2024-12-19 Trial results posted: NCT03322267 Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of RecurrenceResults posted — 2024-12-24 Trial results posted: NCT03092453 Dendritic Cell Vaccination in Patients With Advanced MelanomaResults posted — 2024-12-27 Trial results posted: NCT03468218 Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerResults posted — 2024-12-27 Trial results posted: NCT02723955 Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)Results posted — 2024-12-27 Trial results posted: NCT04157517 A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsResults posted — 2025-01-03 Trial results posted: NCT04682587 To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for theResults posted — 2025-01-09 Trial results posted: NCT03331341 Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin LymphomaResults posted — 2025-01-15 Trial results posted: NCT05191472 Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T TherapiesResults posted — 2025-01-15 Trial results posted: NCT02500576 Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With MetastaticResults posted — 2025-01-16 Trial results posted: NCT03240016 Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial CancerResults posted — 2025-01-17 Trial results posted: NCT03367754 A Single Dose of Pembrolizumab in HIV-Infected PeopleResults posted — 2025-01-20 Trial results posted: NCT02312557 Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With EnzalutamideResults posted — 2025-01-22 Trial results posted: NCT04993677 A Study of SEA-CD40 Given With Other Drugs in CancersResults posted — 2025-01-22 Trial results posted: NCT03016091 A Trial of Pembrolizumab for Refractory Atypical and Anaplastic MeningiomaResults posted — 2025-01-23 Trial results posted: NCT04074759 FPT155 in Patients With Advanced Solid TumorsResults posted — 2025-01-24 Trial results posted: NCT02705820 Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet ChemotherapyResults posted — 2025-01-27 Trial results posted: NCT02662062 Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder CancerResults posted — 2025-01-27 Trial results posted: NCT04533451 Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Results posted — 2025-01-28 Trial results posted: NCT03948763 A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)Results posted — 2025-01-30 Trial results posted: NCT05014776 Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerResults posted — 2025-02-03 Trial results posted: NCT03397654 Study of Pembrolizumab Following TACE in Primary Liver CarcinomaResults posted — 2025-02-06 Trial results posted: NCT03976323 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung CanResults posted — 2025-02-10 Trial results posted: NCT04875195 A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary MediastiResults posted — 2025-02-10 Trial results posted: NCT02733159 Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2Results posted — 2025-02-19 Trial results posted: NCT02907099 Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic CancerResults posted — 2025-02-19 Trial results posted: NCT03222856 Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & TaxanesResults posted — 2025-02-20 Trial results posted: NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal JunctioResults posted — 2025-02-20 Trial results posted: NCT04882241 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal JunctioResults posted — 2025-02-21 Trial results posted: NCT03829319 Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as FirsResults posted — 2025-02-24 Trial results posted: NCT05166577 Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPCResults posted — 2025-02-25 Trial results posted: NCT04322643 Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaResults posted — 2025-02-25 Trial results posted: NCT03805594 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerResults posted — 2025-02-28 Trial results posted: NCT03396926 Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal CancerResults posted — 2025-02-28 Trial results posted: NCT04150900 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and NeckResults posted — 2025-03-06 Trial results posted: NCT03747484 Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell CancerResults posted — 2025-03-10 Trial results posted: NCT04032847 ATL001 in Patients With Advanced Unresectable or Metastatic NSCLCResults posted — 2025-03-10 Trial results posted: NCT04032704 A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsResults posted — 2025-03-10 Trial results posted: NCT02783300 An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in PaResults posted — 2025-03-11 Trial results posted: NCT03137771 Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerResults posted — 2025-03-13 Trial results posted: NCT04284787 BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Results posted — 2025-03-13 Trial results posted: NCT05446129 A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Results posted — 2025-03-17 Trial results posted: NCT04524689 Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With PembrolizumaResults posted — 2025-03-17 Trial results posted: NCT04907851 A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)Results posted — 2025-03-17 Trial results posted: NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or GaResults posted — 2025-03-18 Trial results posted: NCT03914612 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IResults posted — 2025-03-18 Trial results posted: NCT02365766 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC SubjectsResults posted — 2025-03-20 Trial results posted: NCT02437136 Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, MelanomResults posted — 2025-03-21 Trial results posted: NCT04267120 Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell CarcResults posted — 2025-03-24 Trial results posted: NCT03526887 Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLCResults posted — 2025-03-25 Trial results posted: NCT04479241 LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent GlioblastomaResults posted — 2025-03-25 Trial results posted: NCT05267470 A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)Results posted — 2025-03-30 Trial results posted: NCT05834348 A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.Results posted — 2025-04-04 Trial results posted: NCT03197467 Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung CancerResults posted — 2025-04-06 Trial results posted: NCT05665595 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-RisResults posted — 2025-04-06 Trial results posted: NCT04317066 A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-Results posted — 2025-04-08 Trial results posted: NCT03179436 Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)Results posted — 2025-04-08 Trial results posted: NCT04633278 CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaResults posted — 2025-04-16 Trial results posted: NCT03609359 Lenvatinib and Pembrolizumab Simultaneous Combination StudyResults posted — 2025-04-17 Trial results posted: NCT04925986 Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCResults posted — 2025-04-18 Trial results posted: NCT02875132 Pembrolizumab in Advanced/Metastatic Acral Lentiginous MelanomaResults posted — 2025-04-18 Trial results posted: NCT03401853 Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell LyResults posted — 2025-04-20 Trial results posted: NCT04418661 Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesResults posted — 2025-04-29 Trial results posted: NCT04483544 Pembrolizumab and Olaparib in Cervical Cancer PatientsResults posted — 2025-05-02 Trial results posted: NCT03414229 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaResults posted — 2025-05-04 Trial results posted: NCT02638090 Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)Results posted — 2025-05-08 Trial results posted: NCT03747120 Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]Results posted — 2025-05-09 Trial results posted: NCT05323656 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SResults posted — 2025-05-09 Trial results posted: NCT04967417 Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain MetastasesResults posted — 2025-05-11 Trial results posted: NCT05311176 A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing GastricResults posted — 2025-05-11 Trial results posted: NCT03286114 Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With PembrolizumabResults posted — 2025-05-11 Trial results posted: NCT03924869 Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage IResults posted — 2025-05-13 Trial results posted: NCT04082572 Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid CancersResults posted — 2025-05-13 Trial results posted: NCT04383938 Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesResults posted — 2025-05-14 Trial results posted: NCT03390504 A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected FResults posted — 2025-05-15 Trial results posted: NCT03835819 A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)Results posted — 2025-05-16 Trial results posted: NCT03035331 Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaResults posted — 2025-05-16 Trial results posted: NCT04171219 Talabostat and Pembrolizumab for the Treatment of Advanced Solid CancersResults posted — 2025-05-21 Trial results posted: NCT03299088 Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene MutationsResults posted — 2025-05-21 Trial results posted: NCT02799095 A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsResults posted — 2025-05-25 Trial results posted: NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants Results posted — 2025-05-29 Trial results posted: NCT03025035 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast CancerResults posted — 2025-05-30 Trial results posted: NCT04448886 Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBCResults posted — 2025-05-30 Trial results posted: NCT02720068 Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MKResults posted — 2025-05-30 Trial results posted: NCT03242915 Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted AgentsResults posted — 2025-05-31 Trial results posted: NCT04849364 Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerResults posted — 2025-06-03 Trial results posted: NCT04251169 Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor ProgressionResults posted — 2025-06-10 Trial results posted: NCT03582475 Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers oResults posted — 2025-06-11 Trial results posted: NCT02899793 Pembrolizumab in Ultramutated and Hypermutated Endometrial CancerResults posted — 2025-06-12 Trial results posted: NCT03325101 Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable MelanomaResults posted — 2025-06-13 Trial results posted: NCT03867175 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung CancerResults posted — 2025-06-19 Trial results posted: NCT05634577 A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Results posted — 2025-07-01 Trial results posted: NCT05104567 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master ProtocoResults posted — 2025-07-02 Trial results posted: NCT02411656 Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who HavResults posted — 2025-07-02 Trial results posted: NCT03884556 TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced CancersResults posted — 2025-07-03 Trial results posted: NCT02635360 Pembrolizumab and Chemoradiation Treatment for Advanced Cervical CancerResults posted — 2025-07-11 Trial results posted: NCT04120454 Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung CancerResults posted — 2025-07-15 Trial results posted: NCT02940496 Pembrolizumab (MK-3475) in Hepatocellular CarcinomaResults posted — 2025-07-20 Trial results posted: NCT03734692 Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerResults posted — 2025-07-22 Trial results posted: NCT03833167 Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell CarcinoResults posted — 2025-07-25 Trial results posted: NCT03316872 Study of Pembrolizumab and Radiotherapy in Liver CancerResults posted — 2025-07-25 Trial results posted: NCT04904185 ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic MelanomaResults posted — 2025-07-25 Trial results posted: NCT05308901 Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal MelanomaResults posted — 2025-07-28 Trial results posted: NCT05722015 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult ParticiResults posted — 2025-07-29 Trial results posted: NCT05691829 Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLCResults posted — 2025-07-30 Trial results posted: NCT03444376 The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical CancerResults posted — 2025-08-08 Trial results posted: NCT04837196 Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 AntigenResults posted — 2025-08-11 Trial results posted: NCT04164979 Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaResults posted — 2025-08-11 Trial results posted: NCT03695471 Pembrolizumab in Treating Patients With Stage IB-IV Mycosis FungoidesResults posted — 2025-08-11 Trial results posted: NCT02475213 Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerResults posted — 2025-08-17 Trial results posted: NCT04936230 Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial CancerResults posted — 2025-08-24 Trial results posted: NCT03957551 Cabozantinib and Pembrolizumab for Advanced Metastatic MelanomaResults posted — 2025-08-26 Trial results posted: NCT04738487 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-LResults posted — 2025-08-28 Trial results posted: NCT03899805 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue SarcomasResults posted — 2025-08-28 Trial results posted: NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-Results posted — 2025-08-29 Trial results posted: NCT03715205 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in IndiResults posted — 2025-09-04 Trial results posted: NCT04879849 A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersResults posted — 2025-09-09 Trial results posted: NCT04430738 Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersResults posted — 2025-09-09 Trial results posted: NCT03347617 Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With GlioblastomaResults posted — 2025-09-12 Trial results posted: NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women WitResults posted — 2025-09-15 Trial results posted: NCT03307759 Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell LunResults posted — 2025-09-17 Trial results posted: NCT05036681 A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial CarcinomaResults posted — 2025-09-17 Trial results posted: NCT05600309 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 PoResults posted — 2025-09-17 Trial results posted: NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 PoResults posted — 2025-09-18 Trial results posted: NCT04383743 Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder CancerResults posted — 2025-09-22 Trial results posted: NCT05061420 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head Results posted — 2025-09-25 Trial results posted: NCT04768686 FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric CancerResults posted — 2025-09-25 Trial results posted: NCT03184571 Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Results posted — 2025-10-02 Trial results posted: NCT05263492 Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial CancerResults posted — 2025-10-02 Trial results posted: NCT05179603 A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B CeResults posted — 2025-10-02 Trial results posted: NCT04914897 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor LResults posted — 2025-10-06 Trial results posted: NCT03426891 Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed GlioblastomaResults posted — 2025-10-07 Trial results posted: NCT02621151 Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the BladderResults posted — 2025-10-07 Trial results posted: NCT03978624 Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerResults posted — 2025-10-14 Trial results posted: NCT02964013 Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)Results posted — 2025-10-22 Trial results posted: NCT03049618 Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475Results posted — 2025-10-22 Trial results posted: NCT06046482 Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaResults posted — 2025-10-23 Trial results posted: NCT03728972 Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal TypeResults posted — 2025-10-23 Trial results posted: NCT02882282 Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial NeoplasiaResults posted — 2025-10-24 Trial results posted: NCT05091346 A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsResults posted — 2025-10-29 Trial results posted: NCT03069378 A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaResults posted — 2025-10-29 Trial results posted: NCT05469178 A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer PatientResults posted — 2025-10-29 Trial results posted: NCT04828486 Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver CancerResults posted — 2025-11-05 Trial results posted: NCT04370509 Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing SurgeryResults posted — 2025-11-05 Trial results posted: NCT03396445 Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-Results posted — 2025-11-10 Trial results posted: NCT03160079 Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow LymphoblastsResults posted — 2025-11-12 Trial results posted: NCT06212752 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult ParticiResults posted — 2025-11-13 Trial results posted: NCT05226598 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PartResults posted — 2025-11-13 Trial results posted: NCT02959463 Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant MesotheliomaResults posted — 2025-11-17 Trial results posted: NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsResults posted — 2025-11-17 Trial results posted: NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (Results posted — 2025-11-19 Trial results posted: NCT04454489 Quad Shot Radiotherapy in Combination With Immune Checkpoint InhibitionResults posted — 2025-11-19 Trial results posted: NCT04854499 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaResults posted — 2025-11-19 Trial results posted: NCT05775289 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously UnResults posted — 2025-11-19 Trial results posted: NCT05052723 Cabozantinib and Pembrolizumab in Metastatic PancreasResults posted — 2025-11-21 Trial results posted: NCT02706353 APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaResults posted — 2025-11-26 Trial results posted: NCT04570332 BO-112 With Pembrolizumab in Unresectable Malignant MelanomaResults posted — 2025-11-28 Trial results posted: NCT05383170 A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic CancersResults posted — 2025-11-28 Trial results posted: NCT04662710 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic GaResults posted — 2025-12-02 Trial results posted: NCT04373031 Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerResults posted — 2025-12-03 Trial results posted: NCT04704219 Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)Results posted — 2025-12-05 Trial results posted: NCT03007732 Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTResults posted — 2025-12-05 Trial results posted: NCT04090528 pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerResults posted — 2025-12-05 Trial results posted: NCT02437071 Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer PatientsResults posted — 2025-12-08 Trial results posted: NCT03595683 Pembrolizumab and EDP1503 in Advanced MelanomaResults posted — 2025-12-08 Trial results posted: NCT03260504 Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney CancerResults posted — 2025-12-10 Trial results posted: NCT04381650 A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid TumorsResults posted — 2025-12-12 Trial results posted: NCT03310957 Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerResults posted — 2025-12-18 Trial results posted: NCT02819752 PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckResults posted — 2025-12-22 Trial results posted: NCT03095352 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall DiseaseResults posted — 2025-12-24 Trial results posted: NCT03734809 NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal CancerResults posted — 2025-12-24 Trial results posted: NCT05141357 A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung CancerResults posted — 2025-12-31 Trial results posted: NCT03844750 Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic MetastasesResults posted — 2025-12-31 Trial results posted: NCT04601857 Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial CarcinomaResults posted — 2026-01-05 Trial results posted: NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTResults posted — 2026-01-09 Trial results posted: NCT03873818 Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainResults posted — 2026-01-13 Trial results posted: NCT03210662 Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaResults posted — 2026-01-22 Trial results posted: NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsResults posted — 2026-01-22 Trial results posted: NCT02971748 Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy anResults posted — 2026-01-23 Trial results posted: NCT04095689 Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast CancerResults posted — 2026-01-29 Trial results posted: NCT04856189 Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial CarcResults posted — 2026-01-29 Trial results posted: NCT04260529 CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate AccumulationsResults posted — 2026-01-29 Trial results posted: NCT03436056 PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer PatientsResults posted — 2026-01-29 Trial results posted: NCT03474497 UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeResults posted — 2026-01-30 Trial results posted: NCT03815058 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone iResults posted — 2026-01-30 Trial results posted: NCT05814666 Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCResults posted — 2026-02-04 Trial results posted: NCT03727880 Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic DResults posted — 2026-02-04 Trial results posted: NCT04166734 Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural MesotheliomaResults posted — 2026-02-09 Trial results posted: NCT03237572 Focused Ultrasound and Pembrolizumab in Metastatic Breast CancerResults posted — 2026-02-09 Trial results posted: NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsResults posted — 2026-02-12 Trial results posted: NCT04848337 Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerResults posted — 2026-02-12 Trial results posted: NCT03559049 Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerResults posted — 2026-02-12 Trial results posted: NCT03993353 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck CancerResults posted — 2026-02-13 Trial results posted: NCT03123276 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic SarcomaResults posted — 2026-02-17 Trial results posted: NCT04030455 Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal CancerResults posted — 2026-02-20 Trial results posted: NCT03990961 Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)Results posted — 2026-02-24 Trial results posted: NCT02778685 Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen ReceResults posted — 2026-02-27 Trial results posted: NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast CancerResults posted — 2026-02-27 Trial results posted: NCT02446457 Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymResults posted — 2026-02-27 Trial results posted: NCT04268277 Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDYResults posted — 2026-03-04 Trial results posted: NCT04214249 BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Results posted — 2026-03-05 Trial results posted: NCT04222972 A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)Results posted — 2026-03-09 Trial results posted: NCT05116189 Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/EResults posted — 2026-03-09 Trial results posted: NCT02858869 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain MetastasesResults posted — 2026-03-10 Trial results posted: NCT02402920 Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung CancerResults posted — 2026-03-12 Trial results posted: NCT03386357 Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Results posted — 2026-03-12 Trial results posted: NCT03239145 Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorResults posted — 2026-03-18 Trial results posted: NCT04902040 Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Results posted — 2026-03-18 Trial results posted: NCT02642809 Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal CancersResults posted — 2026-03-19 Trial results posted: NCT03276832 Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV MelanomaResults posted — 2026-03-20 Trial results posted: NCT04637594 Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyResults posted — 2026-03-23 Trial results posted: NCT05059470 IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab Results posted — 2026-03-23 Trial results posted: NCT03753659 IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)Results posted — 2026-03-24 Trial results posted: NCT03568058 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced CancersResults posted — 2026-03-24 Trial results posted: NCT04216316 Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to PembrResults posted — 2026-03-25 Trial results posted: NCT03197506 Pembrolizumab and Standard Therapy in Treating Patients With GlioblastomaResults posted — 2026-03-27 Trial results posted: NCT04234113 Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsResults posted — 2026-03-30 Trial results posted: NCT03983668 CMP-001 for Relapsed and Refractory LymphomaResults posted — 2026-04-03 Trial results posted: NCT03428802 Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityResults posted — 2026-04-08 Trial results posted: NCT04869137 Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell CarcinomaResults posted — 2026-04-08 Trial results posted: NCT05077709 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCResults posted — 2026-04-08 Trial results posted: NCT06099782 A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over IntravenoResults posted — 2026-04-09 Trial results posted: NCT03236935 Phase Ib of L-NMMA and PembrolizumabResults posted — 2026-04-13 Trial results posted: NCT04225117 A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Results posted — 2026-04-14 Trial results posted: NCT05232851 A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated OropharResults posted — 2026-04-16 Trial results posted: NCT03634241 Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-LResults posted — 2026-04-20 Trial results posted: NCT04393350 Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaResults posted — 2026-04-23 Trial results posted: NCT02562625 Trial of Pembrolizumab and Radiotherapy in MelanomaResults posted — 2026-04-23 Trial results posted: NCT02587455 Pembrolizumab and Palliative Radiotherapy in LungResults posted — 2026-04-24 Trial results posted: NCT03867084 Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and CoResults posted — 2026-05-01 Trial results posted: NCT04475939 Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants WitResults posted — 2026-05-01 Trial results posted: NCT02837263 PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal CancerResults posted — 2026-05-04 Trial results posted: NCT05379972 Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric CancersResults posted — 2026-05-04 Trial results posted: NCT03752333 Trial of Pembrolizumab in Cancer of Unknown PrimaryResults posted — 2026-05-05 Trial results posted: NCT03144466 A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix CancerResults posted — 2026-05-06 Trial results posted: NCT03349450 DPX-Survivac and Checkpoint Inhibitor in DLBCLResults posted — 2026-05-08 Trial results posted: NCT04414540 Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer PatientsResults posted — 2026-05-08 Trial results posted: NCT02399371 Pembrolizumab in Treating Patients With Malignant MesotheliomaResults posted — 2026-05-12 Trial results posted: NCT04746924 A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerResults posted — 2026-05-13 Trial results posted: NCT02841748 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- theResults posted — 2026-05-13 Trial results posted: NCT04165096 KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With AdvResults posted — 2026-05-13 Trial results posted: NCT04369937 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell CarcinomaResults posted — 2026-05-15 Trial results posted: NCT02444741 Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small CResults posted — 2026-05-20 Trial results posted: NCT03430700 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal CancerResults posted — 2026-05-22 Trial results posted: NCT03095781 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal CancerResults posted — 2026-05-29 Trial results posted: NCT05203445 A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Results posted — 2026-05-29 Trial results posted: NCT02073123 Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaResults posted — 2026-06-03 Trial results posted: NCT04619797 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and CResults posted — 2026-06-04 Trial results posted: NCT04895735 MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland CancerResults posted — 2026-06-04 Trial results posted: NCT04955743 Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaResults posted — 2026-06-08 Trial results posted: NCT03516981 A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTResults posted — 2026-06-08 Trial results posted: NCT04895722 Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-HigResults posted — 2026-06-15 Trial results posted: NCT02987166 HDCRT Plus Pembrolizumab in Advanced MalignanciesResults posted — 2026-06-16 Trial results posted: NCT03657641 Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal CancerResults posted — 2026-06-17 Trial results posted: NCT03213041 Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast CancerResults posted — 2026-06-23 Trial results posted: NCT05996523 Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Results posted — 2026-06-23 Trial results posted: NCT04740307 Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced HepatoceResults posted — 2026-06-23 Trial results posted: NCT04929392 Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or EResults posted — 2026-06-26 Trial results posted: NCT02886585 Pembrolizumab In Central Nervous System MetastasesResults posted — 2026-06-29 Trial results posted: NCT05204290 Study of Combined Decompressive Spine Radiosurgery and PembrolizumabResults posted — 2026-06-30 Trial results posted: NCT04788043 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin LymphomaResults posted — 2026-06-30 Trial results posted: NCT03924895 Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus CystectoResults posted — 2026-07-01 Trial results posted: NCT04924101 Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-StageResults posted — 2026-07-02 Trial results posted: NCT05491317 A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsResults posted — 2026-07-09 Trial results posted: NCT02009449 A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsResults posted — 2026-07-15 Trial results posted: NCT05594043 A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)Results posted — 2026-07-20 Trial results posted: NCT04949256 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Results posted — 2026-07-22 Trial results posted: NCT05167409 Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerResults posted — 2026-07-23 Trial results posted: NCT05714553 NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursResults posted — 2026-07-29 Trial results posted: NCT04576091 Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head andResults posted — 2026-07-31 Trial results posted: NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaResults posted — 2026-08-04 Trial results posted: NCT04887870 Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyResults posted — 2026-08-04 Trial results posted: NCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid TumorsResults posted — 2026-08-07 Trial results posted: NCT05010629 9-ING-41 Plus Carboplatin in Salivary Gland CarcinomaResults posted — 2026-08-11 Trial results posted: NCT06391775 Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination TherapyResults posted — 2026-08-13 Trial results posted: NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsResults posted — 2026-08-13 Trial results posted: NCT04305041 Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (Results posted — 2026-08-17 Trial results posted: NCT03650764 Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaResults posted — 2026-08-17 Trial results posted: NCT03654833 Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaResults posted — 2026-08-24 Trial results posted: NCT02858921 Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaResults posted — 2026-08-27 Trial results posted: NCT04303169 Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With StResults posted — 2026-08-28 Trial results posted: NCT03457948 Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastasestoday (2026-09-01)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-09-01Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Pembrolizumab since 2010, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (382)

2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Upcoming & expected milestones

Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04340882
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT06151574
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations C
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07684599
A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
Primary completion· ClinicalTrials.gov
Primary completion: NCT06532149
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07783581
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the
Primary completion· ClinicalTrials.gov
Primary completion: NCT07485179
Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07619599
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Rec
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT04634877
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07420439
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07756645
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatm
Primary completion· ClinicalTrials.gov
Primary completion: NCT06648057
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
Primary completion· ClinicalTrials.gov
NA primary completion: NCT02194738
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMI
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04253964
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05382325
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07744126
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembroliz
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05186974
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT02444741
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small C
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negativ
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT07762716
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherap
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT07552558
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT06027268
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Primary completion· ClinicalTrials.gov
Primary completion: NCT07718139
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Ca
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04548752
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Ha
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07743190
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Br
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07275216
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07770100
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT04747054
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07788664
Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)

Past events

2026
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07594015
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-ba
Trial started· ClinicalTrials.gov
NA trial started: NCT07629700
Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07541170
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04745988
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in th
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT03257163
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastr
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05901285
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced S
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07732634
RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, L
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT05669352
A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Met
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT06687369
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-sm
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07634094
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07178730
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breas
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04462406
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Results posted· ClinicalTrials.gov
Trial results posted: NCT03457948
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
Results posted· ClinicalTrials.gov
Trial results posted: NCT04303169
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With St
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT04339218
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung A
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT02858921
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT04626518
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT04626479
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT03131908
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT03650764
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT03654833
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06863402
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Results posted· ClinicalTrials.gov
Trial results posted: NCT05572684
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
Results posted· ClinicalTrials.gov
Trial results posted: NCT04305041
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT06391775
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT03244384
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
Results posted· ClinicalTrials.gov
Trial results posted: NCT04887870
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT03108495
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05763004
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a P
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05382325
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07622186
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT03711032
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder C
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT03942653
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT03220477
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Can
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07360743
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
Results posted· ClinicalTrials.gov
Trial results posted: NCT04576091
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06460961
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT05608291
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Comi
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT05167409
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06131398
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT06484153
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06131398
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT04949256
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT03463460
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT04626518
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT04626479
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05614102
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Bo
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05504720
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT05594043
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT02009449
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT04380636
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT05491317
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Results posted· ClinicalTrials.gov
Trial results posted: NCT04924101
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04753879
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05479812
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advan
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07565285
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07275216
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07652242
First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Tripl
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT06687369
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-sm
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Results posted· ClinicalTrials.gov
Trial results posted: NCT04788043
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT07552558
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT03179917
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04708418
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melan
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06153238
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II a
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05816252
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04)
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT05911295
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07593040
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07673887
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06049212
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-0
Results posted· ClinicalTrials.gov
Trial results posted: NCT03924895
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT05083481
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid T
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06551064
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07484139
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamo
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT07302347
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07639242
Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07015853
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT06422806
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT06472076
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT06916416
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05843448
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07178730
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breas
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04123366
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm)
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.